TABLE 3.

Selected drugs that affect genes in the SAGAS database and have evidence of antiseizure efficacy in multiple animal models and from multiple published studies

Drug	Current indications (selected)	Citations	Studies	Models
Riluzole	Amyotrophic lateral sclerosis	482	4	4
Memantine	Alzheimer disease	322	19	5
Verapamil	Angina, hypertension, cluster headache	165	12	6
Meperidine	Pain	155	3	2
Amlodipine	Hypertension, angina	152	4	3
Dextromethorphan	Inflammatory and allergic disorders, congenital adrenal hyperplasia, croup, rheumatic disease	145	22	6
Nifedipine	Angina, hypertension, Raynaud phenomenon, premature labor	86	22	6
Fluoxetine	Depression, bulimia nervosa, obsessive–compulsive disorder	54	11	3
Scopolamine	Motion sickness, excessive respiratory secretions	54	8	3
Aripiprazole	Schizophrenia	52	3	3
Bromocriptine	Parkinson disease, endocrine disorders	52	3	2
Pimozide	Schizophrenia	51	3	4
Apomorphine	Parkinson disease	42	10	4
Bumetanide	Edema	28	5	4
Celecoxib	Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	25	4	2
Dexamethasone	Inflammatory and allergic disorders, congenital adrenal hyperplasia, cerebral edema	25	3	3

Note: "Citations" is the total citations in SAGAS for genes affected by the drug; "Studies" is the number of studies demonstrating antiseizure efficacy of the drug in animal models; "Models" is the number of unique animal models in which the drug has antiseizure efficacy. The complete list of drugs, and PubMed identifiers for the animal model studies reporting their antiseizure efficacy, can be found in Table S4.

Abbreviation: SAGAS, Seizure‐Associated Genes Across Species.